Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis

Irena Ilic1*, Slobodan Jankovic2, Milena Ilic3*

1 Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia, 2 Department of Pharmacology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia, 3 Department of Epidemiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

These authors contributed equally to this work.

* ajrini10@gmail.com

Abstract

Background

Colorectal cancer is one of the leading causes of cancer deaths in both sexes in the world. Improvement of existing therapy modalities and implementing new ones in order to improve survival of patients with colorectal cancer represents a great challenge for medicine. The aim of this paper was to assess the impact that adding bevacizumab to chemotherapy has on survival in patients with metastatic colorectal cancer, compared to the use of chemotherapy alone.

Methods

Hazard ratios (HRs) with their 95% confidence intervals (CI) were determined from the studies and pooled. Two-sided p values were reported and considered to indicate statistical significance if less than 0.05.

Results

A total of 12 studies that meet the inclusion criteria were identified in the literature search, 3 phase II studies and 9 phase III studies. Based on the random effects meta-analysis, a statistically significant improvement was identified for both overall survival (HR = 0.84; 95% CI: 0.74–0.94; p = 0.003) and progression free survival (HR = 0.64; 95% CI: 0.55–0.73; p<0.00001) in patients with metastatic colorectal cancer when bevacizumab was added to chemotherapy, compared to chemotherapy treatment alone.

Conclusion

The findings of this meta analysis confirm the benefit of adding bevacizumab to chemotherapy in terms of survival and progression free survival, but the magnitude of this effect is not consistent throughout the included studies. This suggests the need for further research of
interaction of bevacizumab with chemotherapeutic agents as well as recognition of patients’ characteristics important for the treatment selection criteria.

Introduction
There were over 1.3 million new colorectal cancer cases discovered in 2012 based on the GLOBOCAN estimates, which makes for almost 10 per cent of all malignant tumors [1]. With about 600 000 deaths a year (8% of all deaths from malignancies), an estimated 3.5 million people in the world are living with colon cancer [1]. It is the third most common cancer in men and second in women. The 5-year survival rate for colorectal cancer is estimated to be 65% in North America, 54% in Western Europe, 34% in Central and Eastern Europe and 30% in India, China and Cuba [2]. Colorectal cancer represents a major public health issue and, bearing in mind the epidemiological data on incidence and mortality, the therapy of this disease is a great challenge for medicine. The goal of novel and future research is to improve the existing and introduce new therapeutic modalities in order to improve survival for patients with colorectal cancer.

Classification of colorectal cancer is crucial in choosing the therapy and estimating the rate of survival [3]. Surgical procedures are the main treatment in early stages. In the stage when disease has spread on the surrounding lymph nodes, a combination of anti-tumor drugs, radiation and surgical methods is applied, and in the metastatic stadium chemotherapy is administered. Standard treatment for metastatic colorectal cancer includes different chemotherapy regimens, with or without targeted molecular therapy, and surgical procedures for resectable metastases [4-6]. National Comprehensive Cancer Network’s recommendations for metastatic colorectal cancer chemotherapy include 5-flourouracil or leucovorin (5-FU/LV) with (FOLFOX) or without oxaliplatin, capecitabine with or without oxaliplatin or the use of irinotecan alone or in combination with these drugs [5].

One of the new generations of drugs in oncology, monoclonal antibodies, bind certain cell receptors through which a signal cascade is activated [4, 6, 7]. The use of bevacizumab in therapy of metastatic cancer of different localizations has led to improvement in disease outcome, which laid the groundwork for research of the effects of biological therapy in treatment of metastatic colorectal cancer [6]. In the last few years, bevacizumab, a humanized immunoglobulin G monoclonal antibody which binds to vascular endothelial growth factor, is being introduced in colon cancer treatment alongside chemotherapy [6]. Angiogenesis plays an important role in malignant tumors’ growth and persistence, and vascular endothelial growth factor is one of the central proangiogenic factors under both physiological and pathological conditions. Bevacizumab, by binding to vascular endothelial growth factor, disables its binding to vascular endothelial growth factor receptor and therefore compromises the survival of cancer cells and inhibits their growth. [7, 8]. However, while some studies have shown that the addition of bevacizumab improves survival, the results of other studies have not confirmed these findings [9].

The aim of this paper was to review the results of studies which analyzed the survival benefit that adding bevacizumab to chemotherapy has in patients with metastatic colorectal cancer compared to the use of chemotherapy alone.

Methods
A meta analysis of the survival outcomes from studies with clinical trial design which analyzed the effects of adding bevacizumab to chemotherapy in patients with metastatic colorectal cancer was conducted.
Search strategy
A systematic review of the literature was carried out according to a predefined protocol, in order to identify studies assessing and comparing survival of patients with colorectal cancer who are receiving chemotherapy alone or along with bevacizumab [10]. The PubMed database was searched for eligible articles (up to the end of March 2015). The following keywords were used in the search: "bevacizumab", "metastatic colorectal cancer" and "overall survival". Keywords were formed using the MeSH database (Medical Subject Headings Database). In case of duplicate publications, the most recent papers and those with the most data provided were selected. Finally, the "snowball" method was used, which involved tracking references and citations of found articles in order to identify additional relevant studies.

Study eligibility criteria
Clinical trials investigating the associations between bevacizumab and overall survival in patients with metastatic colorectal cancer were initially reviewed. Two review authors (II and MI), working independently and in parallel, scanned the abstracts and then obtained and reviewed in full only studies that appeared to meet predefined inclusion and not exclusion criteria.

Inclusion criteria: clinical studies including patients with metastatic colorectal cancer, patient randomization to a group of bevacizumab + chemotherapy and chemotherapy-only group for comparison, survival as an outcome, papers in English language.

Exclusion criteria: types of paper such as meta-analyses, systematic reviews, case reports, observational studies, letters to the editor, studies that didn’t have patients assigned to a bevacizumab + chemotherapy and chemotherapy only group and didn’t measure survival as an outcome, studies not performed on humans, papers not in English language.

Quality assessment of included studies
Methodological validity and significance was assessed for every study that met the inclusion criteria. All reviewers independently detected studies for inclusion and then separately assessed validity and significance. Any disagreements were resolved through consensus-based discussion. Quality assessment of included studies was based on the recommendations given by Higgins et al [11] and their principles for assessing risk of bias. Guidance for Assessing the Quality of Controlled Intervention Studies by National Institutes of Health [12] was also used. Methodology of studies was evaluated using available information regarding randomization, blinding, follow up—whether all patients that entered the study were properly accounted for and attributed at its conclusion, whether the groups were treated in the same way apart from the tested treatment, whether groups were similar in the beginning.

Clinical significance of included studies was evaluated by calculating Number Needed to Treat (NNT), as suggested by Altman and Andersen [13] for studies in which outcome is the time to an event. Number needed to treat was calculated using relative risk of response and absolute risk of response [14]. The NNT shows the number of patients needed to treat with the particular drug to see one additional response.

Statistical analyses
Meta analysis was performed using the generic inverse variance method. Review Manager software Version 5.3 [15] was used. The data for ratio measures of intervention effect were entered as natural logarithms and their standard errors. The weight given to each study is the inverse of the variance of the effect estimate. Presented effect estimates were calculated using the random effects model based on the method of DerSimonian and Laird [16]. Outcome of interest, overall
survival (OS), was defined as the time between randomization and any death. Progression free survival (PFS) was defined as the time between randomization and the first occurrence of progression or relapse or death from any cause. Benefit in OS and PFS from adding bevacizumab to standard chemotherapy regimens was assessed using hazard ratio (HR) and its 95% confidence intervals (CI). Data extraction was performed by directly collecting HRs from papers which reported these data. For papers that did not report HRs, software DigitizeIt was used to obtain the needed data from published Kaplan-Meier curves. These calculations were made according to the method proposed by Parmar et al [17], using the spreadsheet developed by Tierney [18]. Using the method proposed by Altman, number needed to treat to benefit and number needed to treat to harm, in terms of survival, were calculated and presented alongside their 95% confidence intervals [19].

Heterogeneity was assessed by calculating I² (variation in effect size attributed to heterogeneity) as suggested by Higgins et al [20]. Clinical relevance of any heterogeneity was estimated by using tau-squared (estimate of between study variance) [21]. Results were graphically presented as forest plots with a diamond representing estimate of the pooled effect and diamond’s width representing its precision; the line of no effect is number one for binary outcomes, which, if not crossed by the diamond, depicts statistical significance. Two-sided p values were reported and considered to indicate statistical significance if less than 0.05.

Presence of publication bias was checked graphically using a funnel plot with effect estimate, hazard ratio, plotted on the horizontal scale and the logarithm of the standard error of hazard ratio plotted on the vertical scale.

**Ethical considerations**

This study is a part of a larger research approved by the Ethics Committee of the Faculty of Medical Sciences, University of Kragujevac (Ref. No.: 01-1176).

**Results**

**Literature search results**

The literature search results, based on the applied keywords and inclusion and exclusion criteria, are shown in Fig 1. This review and meta-analysis included 12 studies, totaling 5888 patients, which compared overall survival and progression free survival in patients with metastatic colorectal cancer receiving either chemotherapy alone or chemotherapy with bevacizumab. Three phase II and nine phase III clinical trials were included in our review.

**Quality assessment of included studies**

Quality assessment of relevant studies was performed using the aforementioned criteria. Randomization was present and explained in detail in 10 studies, in 1 study it was stated to be present but not specified [22], and 1 study had no randomization [23] which authors admitted was a limitation. Blinding of participants and researchers was fully present in 3 studies [22, 24, 25], 2 studies didn’t state whether blinding was applied but only that an independent committee [26] and group of independent radiologists and oncologists [27, 28] had to confirm the collected data. Studies that were open-label [23, 29–33] had response to therapy assessed by an independent committee supervising the study according to Response Evaluation Criteria in Solid Tumors, or had initial data evaluation followed by a central review after which a blind clinician resolved any differences. Overall drop-out rates from the studies at endpoint were up to 20% of the number allocated to treatment. Apart from the treatment in question, other interventions were avoided or similar in the groups. Patients’ baseline demographic and clinical characteristics were well balanced throughout the studies, with authors of one study [22] overcoming gender
distribution differences between study’s arms through adjustments in analysis and with one study [23] showing that differences in gender distribution were not statistically significant. Characteristics and main findings of included trials are shown in Tables 1 and 2.

**Number needed to treat**

Number needed to treat calculated using response rates given in the included studies is shown in Table 3. This table also shows the Number needed to treat to benefit (NNTB) and Number
needed to treat to harm (NNTH), in respect of survival, for addition of bevacizumab to chemotherapy for metastatic colorectal cancer. The values of number needed to treat to benefit show how many patients need to be treated with bevacizumab to see one more additional survival compared to chemotherapy-only regimens, while number needed to treat to harm shows how many patients need to be treated with bevacizumab to see one less good outcome in comparison to chemotherapy-only. These values were calculated for time points of 12 months and 24 months and presented with 95% confidence intervals which, where appropriate, included infinity, as proposed by Altman [21].

Overall survival

Addition of bevacizumab to chemotherapy showed uniform benefit regarding overall survival with HR = 0.84; 95% CI: 0.76–0.94; p = 0.003. Because high heterogeneity was observed between trials (I² = 58%; p = 0.004), subgroup analyses were performed according to the chemotherapy regimen (Fig 2). Statistically significant benefit in overall survival was present in

| Researcher, year of publication (reference) | Progression-free survival (months) | Response rate (%) | Overall survival (months) |
|--------------------------------------------|-----------------------------------|-------------------|--------------------------|
| Kabbinavar et al., 2003 (22)               | 5.2 vs 9.0 vs 7.2                  | 17 vs 40 vs 24    | 13.8 vs 21.5 vs 16.1     |
| Moehler et al., 2009 (23)                  | 11.4 vs 12.8                       | 29.4 vs 34.5      | 15 vs 24                 |
| Hurwitz et al., 2005 (24)                  | 6.8 vs 8.8                         | 37 vs 40          | 15.1 vs 18.3             |
| Hurwitz et al., 2004 (25)                  | 6.2 vs 10.6                        | 34.8 vs 44.8      | 15.6 vs 20.3             |
| Saltz et al., 2008 (26)                    | 8.0 vs 9.4                         | 49 vs 47          | 19.9 vs 21.3             |
| Stathopoulos et al., 2010 (27)             | 35.2 vs 36.8                       | 22 vs 25          |                          |
| Kabbinavar et al., 2005 (28)               | 5.5 vs 9.2                         | 15.2 vs 26        | 12.9 vs 16.6             |
| Guan et al., 2011 (29)                     | 4.2 vs 8.3                         | 17 vs 35          | 13.4 vs 18.7             |
| Giantonio et al., 2007 (30)                | 4.7 vs 7.3 vs 2.7                  | 8.6 vs 22.7 vs 3.3| 10.8 vs 12.9 vs 10.2    |
| Tebutt et al., 2010 (31)                   | 5.7 vs 8.5 vs 8.4                  | 30.3 vs 38.1 vs 45.9| 18.9 (C) vs 16.4         |
| Cunningham et al., 2013 (32)               | 5.1 vs 9.1                         | 10 vs 19          | 16.8 vs 20.7             |
| Passardi et al., 2015 (33)                 | 8.4 vs 9.6                         | 50 vs 50.6        | 21.3 vs 20.8             |

Abbreviations: FU = 5-flourouracil; LV = leucovorin; BV = bevacizumab; CAPIRI = capecitabine + irinotecan; IFL = irinotecan + bolus 5-FU + leucovorin; XELOX = capecitabine + oxaliplatin; FOLFOX4 = 5-FU + LV + oxaliplatin; mIFL = modified IFL; FOLFIRI = leucovorin + 5-FU + irinotecan; CM = capecitabine + mitomycin; CMB = capecitabine + mitomycin + B.
fluorouracil monotherapy (HR = 0.71; 95% CI: 0.61–0.83; p < 0.0001) and oxaliplatin based chemotherapy regimens (HR = 0.83; 95% CI: 0.74–0.93; p = 0.001), while the results for irinotecan based and capecitabine regimens did not reach statistical significance. Sensitivity analysis aimed to detect the influence of three phase II studies showed results to remain stable when these studies were included or excluded from analysis (Fig 3).

Progression free survival

Benefit in progression free survival was evident when bevacizumab was added to chemotherapy (HR = 0.64; 95% CI: 0.55–0.73; p < 0.00001), but with high heterogeneity (I^2 = 63%; p = 0.002) (Fig 4). However, subgroup analysis showed that the increment in PFS was persistent throughout all chemotherapy regimens to which bevacizumab was added, with oxaliplatin based regimens showing the least but still significant benefit (HR = 0.73; 95% CI: 0.54–0.98; p = 0.04) and addition to fluorouracil monotherapy showing the most benefit (HR = 0.52; 95% CI: 0.38–0.70; p < 0.0001) (Fig 5).

Funnel plots (Fig 6 and Fig 7) were used for assessing publication bias. The lines representing 95% confidence intervals for each summary effect show the expected distribution of studies in the absence of selection bias or heterogeneity [34]. Funnel plots are relatively symmetrical for both OS (Fig 6) and PFS (Fig 7), and since the asymmetry is not pronounced, it is not likely that the amount of publication bias is substantial.

Discussion

Bevacizumab is a drug that targets vascular endothelial growth factor and, as such, is widely investigated in clinical trials with cancer patients. Studies that included patients with metastatic colorectal cancer have tested it alongside different chemotherapy protocols, and this research yielded various results. These variations could find a possible explanation in studies’ settings, their methodological quality and in interactions of bevacizumab with chemotherapeutic agents. Our meta-analysis showed that the addition of bevacizumab to chemotherapy in patients with metastatic colorectal cancer prolongs overall survival and progression free survival.

| Researcher, year of publication (reference) | Bevacizumab dose | NNT for response | NNTB and NNTH–survival |
|---------------------------------------------|------------------|------------------|------------------------|
| Kabbinavar et al., 2003 (22)                | 5 mg/kg; 10 mg/kg| 4: 14            | NNTB 9 (6–20)          |
| Moehler et al., 2009 (23)                   | 7.5 mg/kg        | 20               | NNTB 7 (NNB 2 to NNTH 6) |
| Hurwitz et al., 2005 (24)                   | 5 mg/kg          | 33               | NNTB 10 (NNTH 4 to NNTH 29) |
| Hurwitz et al., 2004 (25)                   | 5 mg/kg          | 10               | -                      |
| Saltz et al., 2008 (26)                     | 7.5 mg/kg; 5 mg/kg| RR equal (38%)   | NNTB 16 (9–63)         |
| Stathopoulos et al., 2010 (27)             | 7.5 mg/kg        | 63               | NNTB 40 (NNTH 8 to NNTH 13) |
| Kabbinavar et al., 2005 (28)               | 5 mg/kg          | 9                | NNTB 10 (NNTH 31 to NNTH 4) |
| Guan et al., 2011 (29)                      | 5 mg/kg          | 6                | NNTB 7 (NNTH 4 to NNTH 1250) |
| Giantonio et al., 2007 (30)                 | 10 mg/kg         | 7                | NNTB 8 (5–21)          |
| Tebut et al., 2010 (31)                     | 7.5 mg/kg        | 13; 6            | NNTB 15 (NNTH 6 to NNTH 27) |
| Cunningham et al., 2013 (32)               | 7.5 mg/kg        | 11               | NNTB 8 (4–53)          |
| Passardi et al., 2015 (33)                  | 5 mg/kg          | 167              | NNTB 13 (NNTH 6 to NNTH 101) |

Abbreviations: NNT = Number needed to treat; RR = Response rate; NNTB = Number needed to treat to benefit; NNTH = Number needed to treat to harm.

doi:10.1371/journal.pone.0161912.t003
Subgroup analysis by chemotherapy regimens used as the backbone of metastatic colorectal treatment shows that differences in benefit from adding bevacizumab exist. Overall survival was improved by adding bevacizumab (HR = 0.84). However, the subgroup analysis showed this effect to remain statistically significant only for fluorouracil monotherapy and oxaliplatin based regimens. When bevacizumab was added to irinotecan based regimens and capecitabine, the benefit in OS was still present but did not reach statistical significance. These findings suggest that interactions of bevacizumab with chemotherapeutic agents exist, and as such might explain the observed heterogeneity. For PFS, differences in the magnitude of bevacizumab addition effect were not as pronounced. Improvement in PFS was statistically significant (HR = 0.64), and remained so throughout different chemotherapy regimens in the subgroup analysis.

The NNT evaluated in this paper is a matter that should be further assessed. Our findings suggest that the effect of the addition of bevacizumab to chemotherapy varies among different chemotherapy regimens, different doses, but also possibly different patient’s characteristics, regarding the location of the primary tumour among others. Presence and impact of such influencing variables should be detected and weighted, which might be applicable to the selection criteria for patients in the future.

Findings of this review and meta-analysis are in concordance with those previously published. This review included new studies, detected through the search of literature based on the
predefined criteria. The effect of bevacizumab on survival in patients with various cancer localizations, compared to control treatment, was assessed in meta-analyses [35,36–38] which showed that the use bevacizumab in patients with metastatic colorectal cancer was linked with
a significantly greater OS and PFS. A pooled analysis of individual patient data [39] of 7 randomised clinical trials that included 3763 patients found a statistically significant increase in OS (18.7 months vs 6.4 months, \( p = 0.0003 \)) and PFS (8.8 months versus 6.4 months, \( p < 0.0001 \)) in the group of patients who received bevacizumab in combination with chemotherapy. Authors performed a subgroup analysis according to chemotherapy protocol and confirmed these findings both for irinotecan and oxaliplatin based regimens, while our subgroup analysis did not find statistically significant benefit in OS for irinotecan based chemotherapy regimens (HR = 0.87, 95% CI 0.61–1.24; \( p = 0.44 \)). These OS findings for the combination of bevacizumab with irinotecan based regimens are mostly influenced by one study [27] whose authors hypothesize that OS would have been greater if bevacizumab was used in maintenance treatment, because it is assumed to act as a chemotherapy-sensitizing agent. One systematic review and meta-analysis [40] evaluated the effect of adding bevacizumab to various chemotherapy protocols and found that BV significantly (\( p < 0.00001 \)) improved OS (greatest benefit found in combination with irinotecan) and PFS (greatest benefit found in combination with fluorouracil). Results of our subgroup analysis were in concordance with these regarding PFS, while for OS we found combination with fluorouracil to be the most beneficial. Authors explained that the results of their subgroup analysis for OS [40] were influenced by one single study, which might provide an explanation for these differences. Chen et al [41] found no overall survival benefit from adding bevacizumab to chemotherapy, and after performing a subgroup analysis

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------------------|
| Kabbmini, 2003    | -0.6162          | 0.2481 | 5.3%   | 0.54 [0.33, 0.88]           |
| Kabbmini, 2005    | -0.6931          | 0.1966 | 7.0%   | 0.50 [0.34, 0.74]           |
| Subtotal (95% CI) | 12.3%            | 0.52 [0.38, 0.70] |

Heterogeneity: \( \text{Tau}^2 = 0.00; \text{Chi}^2 = 0.06; df = 1 (P = 0.01); \text{I}^2 = 0% \)

Test for overall effect: \( Z = 4.30 (P < 0.0001) \)

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------------------|
| Guan, 2011        | -0.821           | 0.2495 | 5.3%   | 0.44 [0.27, 0.72]           |
| Hurwitz, 2004     | -0.6162          | 0.1873 | 7.4%   | 0.54 [0.37, 0.76]           |
| Hurwitz, 2005     | -0.1508          | 0.1852 | 7.4%   | 0.80 [0.60, 1.14]           |
| Moehler, 2009     | -0.3403          | 0.3411 | 3.4%   | 0.71 [0.36, 0.89]           |
| Passard, 2015     | -0.1508          | 0.1082 | 11.2%  | 0.86 [0.70, 1.06]           |
| Subtotal (95% CI) | 34.6%            | 0.68 [0.52, 0.89] |

Heterogeneity: \( \text{Tau}^2 = 0.05; \text{Chi}^2 = 9.77; df = 4 (P = 0.04); \text{I}^2 = 59% \)

Test for overall effect: \( Z = 2.60 (P = 0.005) \)

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------------------|
| Giancovi, 2007    | -0.4943          | 0.1502 | 9.0%   | 0.61 [0.45, 0.82]           |
| Saltz, 2008       | -0.1863          | 0.0707 | 13.1%  | 0.83 [0.72, 0.95]           |
| Subtotal (95% CI) | 22.1%            | 0.73 [0.54, 0.98] |

Heterogeneity: \( \text{Tau}^2 = 3.44; \text{Chi}^2 = 1 (P = 0.06); \text{I}^2 = 71% \)

Test for overall effect: \( Z = 2.06 (P = 0.04) \)

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI |
|-------------------|------------------|----|--------|-----------------------------|
| Cunningham, 2013  | -0.6349          | 0.1320 | 9.9%   | 0.53 [0.41, 0.69]           |
| Tebbutt, 2010 I   | -0.4716          | 0.1188 | 10.6%  | 0.62 [0.49, 0.76]           |
| Tebbutt, 2010 II  | -0.5652          | 0.1203 | 10.5%  | 0.66 [0.44, 0.71]           |
| Subtotal (95% CI) | 31.0%            | 0.67 [0.50, 0.66] |

Heterogeneity: \( \text{Tau}^2 = 0.00; \text{Chi}^2 = 2 (P = 0.63); \text{I}^2 = 0% \)

Test for overall effect: \( Z = 7.63 (P < 0.00001) \)

Total (95% CI) 100.0% 0.64 [0.55, 0.73]

Heterogeneity: \( \text{Tau}^2 = 0.03; \text{Chi}^2 = 29.46; df = 11 (P = 0.002); \text{I}^2 = 63% \)

Test for overall effect: \( Z = 6.37 (P < 0.00001) \)

Test for subgroups differences: \( \text{Chi}^2 = 4.06; df = 3 (P = 0.26); \text{I}^2 = 26.0% \)

Fig 5. Meta-analysis of progression free survival data by chemotherapy regimen. Abbreviations: SE = Standard Error; 95% CI = 95% Confidence Interval; Chi² = Chi-squared test; df = degree of freedom; Tau² = Tau-squared; I² = I-squared; P = Probability.

doi:10.1371/journal.pone.0161912.g005
Fig 6. Funnel plot for publication bias assessment regarding overall survival. Abbreviation: SE = Standard Error.
doi:10.1371/journal.pone.0161912.g006

Fig 7. Funnel plot for publication bias assessment regarding progression-free survival. Abbreviation: SE = Standard Error.
doi:10.1371/journal.pone.0161912.g007
suggested it existed only in combination with capecitabine, while they did find benefit in PFS. Reasons for these findings regarding OS might be due to insufficient data available from the ITACa trial [33] at that time, which was acknowledged by the authors [41]. Contrary to this, another meta-analysis [42] found benefit in both OS and PFS when bevacizumab was added to chemotherapy, with the subgroup analysis for OS showing it to be consistent across all chemotherapy regimens except capecitabine.

Strengths and limitations of this review and meta analysis

The incidence and mortality from colorectal cancer give strong implications for undertaking this review. To our knowledge, this review includes studies which are new in comparison to previously published reviews and meta analyses. In addition to presenting pooled HR for OS and PFS, we have also calculated number of patients with metastatic colorectal cancer which need to be treated with bevacizumab to gain one more response, and number needed to treat to benefit or harm, in terms of survival, alongside corresponding 95% confidence intervals. The limitation of this meta analysis is the lack of individual patient data. Also, estimating HRs from Kaplan-Meier curves, which was necessary for studies that did not report this effect measure, is another issue. Literature search which included only studies in English language was a limitation because it may have led to omitting a study published in another language.

The review of included studies showed that the addition of bevacizumab to chemotherapy in patients with metastatic colorectal cancer is associated with greater overall survival, longer progression-free survival and a better response rate compared to chemotherapy treatment alone. Although some studies showed that adding bevacizumab significantly improved survival, the results of other studies have not confirmed these findings in respect of statistical significance. Our meta-analysis combined data from 12 clinical studies and showed that adding bevacizumab to chemotherapy provides a statistically significant benefit in overall survival and progression free survival. Further investigation of survival benefit from adding bevacizumab to standard chemotherapy is needed, both in first line setting and treatment after disease progression, with emphasis on the chemotherapy protocol used as the treatment backbone. Also, studies evaluating overall survival alongside quality of life in patients with metastatic colorectal cancer are considered to be of great necessity for future research.

Supporting Information

S1 File. PRISMA Checklist.
(DOC)

Acknowledgments

Authors thank the team of the Serbian Society for Rational Therapy in Medicine (MEDRAT®, web:www.medrat.edu.rs) for the English language editing of the manuscript.

Author Contributions

Conceptualization: II.
Data curation: II MI.
Formal analysis: II.
Investigation: II MI.
Methodology: II MI.
References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–386. doi: 10.1002/ijc.29210 PMID: 25220842

2. Lee YC, Lee YL, Chuang JP, Lee JC. Differences in survival between colon and rectal cancer from SEER data. PLoS One 2013; 8(11):e78709. doi: 10.1371/journal.pone.0078709 PMID: 24265711

3. Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, et al. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis. 2012; 27(5):657–663. doi: 10.1007/s00384-011-1366-6 PMID: 22146786

4. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A; ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v70–77. doi: 10.1093/annonc/mdq168 PMID: 20555107

5. Hung A, Mullins CD. Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. Oncologist 2013; 18(1):54–63. doi: 10.1634/theoncologist.2012-0050 PMID: 2399774

6. Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol. 2011; 29(1):1–4. doi: 10.1200/JCO.2010.32.2701 PMID: 2115866

7. Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 2014; 17(3):471–494. doi: 10.1007/s10456-014-9420-y PMID: 24482243

8. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006; 93(12):1456–1463. PMID: 17115389

9. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Lopa SH, et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol. 2013; 31(3):359–364. doi: 10.1200/JCO.2012.44.4711 PMID: 23233715

10. Moher D, Liberati A, Tetzlaff J, Altman DG; The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6: e1000097 doi: 10.1371/journal.pmed.1000097 PMID: 19621072

11. Higgins JPT, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928 doi: 10.1136/bmj.d5928 PMID: 22008217

12. National Institutes of Health. Quality Assessment of Controlled Intervention Studies. General Guidance for Determining the Overall Quality Rating of Controlled Intervention Studies. National Heart, Lung, and Blood Institute: Bethesda, MD; 2015.

13. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999; 319(7223):492–495. PMID: 10582940

14. Spitalnic Stuart. “Risk assessment I: Relative risk and absolute risk reduction.” Hospital physician 2005; 44:43–46.

15. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

16. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org

17. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17(24):2815–2834. PMID: 9921604
18. Tierney JF, Stewart LA, Gherisi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMID: 17555582
19. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998; 317(7168):1309–1312. PMID: 9804726
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557–560. PMID: 12958120
21. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008; 8:79. doi:10.1186/1471-2288-8-79 PMID: 19036172
22. Kabbainavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003; 21(1):60–65. PMID: 12506171
23. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol. 2009; 15(4):449–456. PMID: 19152449
24. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an oncology regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23(15):3502–3508. PMID: 15908660
25. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23):2335–2342. PMID: 15175435
26. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figuer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12):2013–2019. doi:10.1200/JCO.2007.14.9930 PMID: 18421054
27. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batziou S, Stathopoulos J, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78(5–6):376–381. doi: 10.1159/000320520 PMID: 20798560
28. Kabbainavar FF, Schulz J, McLeod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23(16):3697–3705. PMID: 15738537
29. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011; 30(10):682–689. doi:10.5732/cjc.11.10188 PMID: 21959045
30. Giontonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12):1539–1544. PMID: 17442997
31. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Effects of bevacizumab, capecitabine, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010; 28(19):3191–3198. doi:10.1200/JCO.2009.27.7723 PMID: 20516443
32. Cunningham D, Lang I, Marcuello E, Lorusso V, Occhini J, Shin DB, et al; AVEX study investigators. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077–1085. doi:10.1016/S1470-2045(13)70154-2 PMID: 24028813
33. Passardi A, Nanni O, Tassinari D, Turci D, Cavanna L, Fontana A, et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol. 2015; 26(6):1201–1207. doi: 10.1093/annonc/mdv130 PMID: 25735317
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–634. PMID: 9310563
35. Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012; 7(4):e35629. doi: 10.1371/journal.pone.0035629 PMID: 22539986
36. Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors—a meta-analysis and systematic review. PLoS One 2013; 8(1):e51780. doi: 10.1371/journal.pone.0051780 PMID: 23349675
37. Welch S, Spithoff K, Rumble RB, Maroun J; Gastrointestinal Cancer Disease Site Group. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010; 21(6):1152–1162. doi:10.1093/annonc/mdp533 PMID: 19942597

38. Zhang G, Zhou X, Lin C. Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. Int J Clin Exp Med 2015; 8(1):1434–1445. PMID: 25785152

39. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, et al. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 2013; 18(8):1004–1012. doi:10.1634/theoncologist.2013-0107 PMID: 23881988

40. Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 2012; 12:89. doi:10.1186/1471-2407-12-89 PMID: 22414244

41. Chen Y, Yang Q, Kuang J, Chen SY, Wei Y, Jiang ZM, et al. Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials. Gastroenterol Res Pract. 2014; 2014:594930. doi:10.1155/2014/594930 PMID: 24971091

42. Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X. The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biother Radiopharm. 2013; 28(7):501–509. doi:10.1089/cbr.2012.1458 PMID: 23768086